List of Excipients in Branded Drug CARGLUMIC ACID

Generic Drugs Containing CARGLUMIC ACID

Company	Ingredient	NDC	Excipient
Burel Pharmaceuticals LLC	carglumic acid	35573-459	CELLULOSE, MICROCRYSTALLINE
Navinta LLC	carglumic acid	68475-006	CELLULOSE, MICROCRYSTALLINE
Navinta LLC	carglumic acid	68475-006	CROSCARMELLOSE SODIUM
Navinta LLC	carglumic acid	68475-006	MICROCRYSTALLINE CELLULOSE 105
Navinta LLC	carglumic acid	68475-006	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in CARGLUMIC ACID?

# Of NDCs	Excipient
4	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM
2	MAGNESIUM STEARATE
2	MANNITOL
1	MICROCRYSTALLINE CELLULOSE 105

Carglumic Acid Excipient Strategy and Commercial Opportunities

Last updated: September 8, 2026

Carglumic acid is a small-molecule orphan metabolic drug marketed primarily as Carbaglu, a 200 mg dispersible tablet for oral suspension. The main commercial opportunities are generic or regional products that preserve rapid dispersion, pediatric usability, dose flexibility, and chemical stability while reducing manufacturing cost. Excipient selection is central because the dosage form is administered after dispersion in water rather than swallowed as a conventional tablet.

What is the regulatory and commercial status of carglumic acid?

Carglumic acid, also known as N-carbamoyl-L-glutamic acid, is a synthetic structural analog of N-acetylglutamate. It activates carbamoyl phosphate synthetase I and restores urea-cycle activity in patients with N-acetylglutamate synthase deficiency. In the United States, the approved product is Carbaglu tablets for oral suspension, 200 mg.

Attribute	Public regulatory position
Active ingredient	Carglumic acid
Reference product	Carbaglu
Dosage form	Tablet for oral suspension
Strength	200 mg
FDA approval	NAGS deficiency in 2010; supplemental indication for acute hyperammonemia associated with propionic acidemia and methylmalonic acidemia in 2015
Primary patients	Pediatric and adult patients, depending on indication and treatment phase
Administration	Disperse tablet in water before oral administration
Drug category	Small molecule, not a biologic
Biosimilar pathway	Not applicable
Orphan status	Granted for rare metabolic indications
Current commercial issue	Supply reliability, pediatric administration, specialty distribution, and generic substitution

The approved product uses a dispersible tablet rather than an oral solution. That format lowers shipping and microbial-control burdens, but it places greater demands on disintegration, dispersion uniformity, taste, and dose administration. The FDA label states that tablets should be dispersed in water and administered promptly; they should not be swallowed whole.[1]

Carglumic acid has no biosimilar exposure because it is a chemically defined small molecule. Competitive risk comes from generic carglumic acid tablets, alternative oral presentations, extemporaneous pharmacy preparations, and regional products.

What excipients are used in Carbaglu?

Public labeling identifies a conventional immediate-release excipient system designed to support tablet manufacture and aqueous dispersion. The U.S. product label lists microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, hypromellose, colloidal silicon dioxide, and talc as inactive ingredients.[1]

Excipient	Likely formulation function	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports tablet strength at a relatively high active load
Croscarmellose sodium	Superdisintegrant	Promotes rapid breakup after addition to water
Sodium lauryl sulfate	Wetting agent	Improves wetting of hydrophobic or poorly wettable particles
Hypromellose	Binder and film-forming or matrix-control excipient	Supports mechanical integrity and processability
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and blend uniformity
Talc	Processing aid and anti-adherent	Reduces sticking during compression

The exact functional performance of each excipient must be demonstrated in the finished product. A generic developer cannot assume that matching the inactive-ingredient list alone will reproduce dispersion time, sedimentation behavior, dose uniformity, or stability.

What excipient strategy is optimal for a generic carglumic acid product?

The strongest generic strategy is a high-load, immediate-release dispersible tablet with a simple, well-characterized excipient platform. The target is pharmaceutical equivalence to the reference product without unnecessary formulation complexity.

1. Prioritize rapid and uniform dispersion

The product should disperse rapidly in a practical volume of water, produce a consistent suspension, and avoid large sedimented particles. Key development measurements include:

• Disintegration time in water;
• Dispersion time under labeled-use conditions;
• Particle-size distribution after dispersion;
• Sedimentation rate;
• Redispersibility;
• Dose recovery from the preparation vessel;
• Content uniformity across the first and last portions administered.

Croscarmellose sodium is a logical primary disintegrant. Crospovidone or sodium starch glycolate could be evaluated as alternatives, but substitution may change swelling, dispersion texture, and sedimentation. A dual-disintegrant system may improve robustness but increases formulation and regulatory complexity.

2. Control wetting without compromising tolerability

Sodium lauryl sulfate can improve wetting and dispersion. Its concentration should remain as low as necessary because excessive surfactant may increase foaming, alter taste, or cause gastrointestinal intolerance. Polysorbates or poloxamers could be considered during development, but they may create new extractables, compatibility, or sensory issues.

For a pediatric rare-disease product, excipient selection should consider cumulative exposure. FDA guidance places particular importance on excipient safety in pediatric products, especially when the product is administered chronically.[2]

3. Protect chemical and physical stability

Carglumic acid contains carboxylic acid functionality and an amino-acid-derived structure. Development should assess:

• Water activity and moisture uptake;
• Hydrolytic and oxidative degradation;
• Compatibility with alkaline or acidic excipients;
• Residual moisture after granulation;
• Packaging-barrier performance;
• Stability after tablet dispersion;
• Light sensitivity;
• Metal-ion interactions.

A low-moisture direct-compression process may reduce degradation risk and manufacturing cost. Wet granulation may improve content uniformity and compressibility but can increase exposure to water and drying stress. The preferred process depends on powder flow, tablet hardness, and active-excipient compatibility.

4. Preserve dose flexibility

Carglumic acid treatment can require weight-based dosing and dose adjustment during acute hyperammonemia. A 200 mg tablet may therefore be used in combinations that do not correspond to a single whole-tablet dose. A product that disperses uniformly allows caregivers and clinicians to administer partial volumes more reliably.

Commercial opportunities include:

• Lower-strength tablets;
• Multi-strength packs;
• Unit-dose sachets or granules;
• Ready-to-use oral suspension;
• Hospital-use powder for reconstitution;
• Pediatric administration devices calibrated for dispersed product.

Lower-strength presentations may improve dosing accuracy but increase SKU complexity, packaging cost, and inventory requirements. A 100 mg strength could be commercially attractive for small children if the regulatory and market volumes justify the additional presentation.

What formulations are protected or commercially differentiated?

The core commercial differentiation is the delivery format, not a novel mechanism. The reference product's tablet-for-oral-suspension design creates several potential formulation segments.

Dispersible tablets

This is the closest generic opportunity. Development priorities are pharmaceutical equivalence, rapid dispersion, acceptable taste, and stable packaging. The main barriers are not patent complexity alone; they include reproducible performance across manufacturing sites and reliable administration by caregivers.

Oral granules

Granules can offer improved dose flexibility and potentially better dispersion. They may also permit sachet-based unit dosing. The tradeoff is greater packaging surface area, more complicated filling operations, and possible moisture sensitivity.

Ready-to-use oral liquids

An oral liquid could improve administration for infants and patients unable to prepare a dispersion. Its disadvantages include preservative selection, microbial control, bulkier distribution, shorter in-use stability, and higher shipping costs. A liquid product may be commercially valuable in hospitals and specialty pharmacies even if its manufacturing cost is higher.

Taste-masked products

Carglumic acid products may encounter sour, acidic, or otherwise challenging taste characteristics because of the molecule's acid functionality. Taste masking can use flavor systems, sweeteners, polymer coatings, ion-exchange approaches, or multiparticulate encapsulation. However, taste-masking excipients must not delay dispersion or reduce delivered dose.

A simple flavored dispersion may be more practical than a coated tablet because coating can slow wetting and complicate equivalence. Sweeteners and flavors should be selected with attention to metabolic disease populations and chronic pediatric use.

When does carglumic acid lose exclusivity?

The original U.S. orphan-drug exclusivity period for N-acetylglutamate synthase deficiency followed Carbaglu's 2010 approval. The later propionic acidemia and methylmalonic acidemia indication received separate regulatory protection associated with the 2015 supplemental approval. Orphan exclusivity is indication-specific and does not prevent all forms of generic development for other indications.[3]

The commercial position should be separated into four categories:

Protection category	Relevance to carglumic acid
Orphan-drug exclusivity	Historical indication-specific protection; the original periods have elapsed
Patent protection	Must be assessed by patent family, claim scope, terminal disclaimers, and Orange Book listing
Pediatric exclusivity	May extend listed regulatory protections by six months when granted
Regulatory exclusivity for a generic	Depends on the first approved ANDA and Paragraph IV outcome

Public regulatory materials establish the approval history, but the current patent position requires review of FDA Orange Book listings, issued patent records, litigation dockets, and any unlisted manufacturing or formulation claims.[4] A generic applicant should not rely only on the absence of an obvious active-ingredient patent. Formulation, method-of-use, crystalline-form, process, and packaging claims can affect launch timing.

What Paragraph IV challenges and generic launch risks exist?

A Paragraph IV applicant would typically evaluate whether listed patents are invalid, unenforceable, or not infringed. For carglumic acid, the main technical arguments would likely focus on:

• Whether the proposed dispersible tablet falls within formulation claims;
• Whether the same or equivalent use is covered by method-of-use claims;
• Whether a formulation claim requires a specific excipient ratio or dispersion profile;
• Whether manufacturing claims are infringed by the applicant's process;
• Whether the reference product's listed claims remain enforceable at the intended launch date.

Generic launch scenarios include:

1. First-filer launch after patent certification. This can create a period of market exclusivity if statutory conditions are satisfied.
2. At-risk launch. The applicant launches before final patent resolution, accepting possible damages or injunctive exposure.
3. Post-expiration launch. The applicant waits for patent expiry and avoids litigation risk but may lose first-mover value.
4. Indication-limited launch. A carve-out can avoid a protected use while retaining approval for unprotected indications, subject to labeling and regulatory requirements.
5. Authorized generic or settlement launch. A license or settlement may define entry timing, supply terms, or geographic rights.

No broad biosimilar challenge exists because carglumic acid is not a biologic. The relevant litigation question is generic patent litigation, including ANDA-related proceedings under the Hatch-Waxman framework.

How strong is the carglumic acid patent estate?

Patent strength depends less on the existence of a single active-ingredient patent than on the enforceability and commercial relevance of secondary patents. The strongest potential barriers would cover the marketed dosage form or a manufacturing process that is difficult to design around.

Patent layer	Likely strength	Design-around potential
Active ingredient	Low if basic composition claims have expired	Usually high
Therapeutic use	Moderate, depending on indication language	Moderate through labeling carve-outs
Dispersible tablet	Moderate to high if performance is claim-limited	Moderate
Excipient combination	Moderate if narrowly claimed	High to moderate
Granules or oral liquid	Variable	Often high
Manufacturing process	Moderate if process-specific and economical	Moderate
Packaging and stability	Usually low to moderate	High

A formulation patent is commercially meaningful only if it covers a necessary product attribute, such as dispersion performance, stability, or dose uniformity. A narrow claim to a particular excipient ratio may be easier to design around by changing the disintegrant, binder, surfactant, or manufacturing process.

What licensing and commercial opportunities exist?

Carglumic acid has a specialty-market profile: low patient volume, high clinical importance, concentrated prescriber networks, and potentially high treatment value per patient. Commercial opportunities are therefore more likely to arise from supply reliability and product access than from mass-market volume.

Generic and regional licensing

Potential deal structures include:

• Regional commercialization rights for a generic dispersible tablet;
• Contract manufacturing with secondary-source qualification;
• Licensing of a pediatric oral liquid or granule formulation;
• Hospital and specialty-pharmacy supply agreements;
• Co-development of lower-strength presentations;
• Distribution partnerships in markets where the reference product is unavailable or expensive.

Manufacturing opportunities

A manufacturer can create value through:

• Direct compression with high-throughput tablet production;
• Low-moisture processing;
• Dedicated packaging for moisture protection;
• Dual sourcing of critical excipients;
• Standardized in-use dispersion testing;
• Small-batch manufacturing for orphan markets;
• Flexible packaging for international dose instructions.

Manufacturing barriers include low forecast volumes, demand volatility tied to diagnosis rates, specialized pharmacovigilance requirements, and the need to maintain uninterrupted supply for patients with acute hyperammonemia.

Revenue exposure

Public filings generally do not provide a reliable standalone revenue figure for carglumic acid across all markets. Revenue depends on indication mix, country reimbursement, specialty-distribution contracts, orphan pricing, generic entry, and treatment duration. The highest-value commercial segment is likely chronic NAGS deficiency, while acute hyperammonemia indications can create episodic hospital demand.

How does carglumic acid compare with competing ammonia-lowering therapies?

Carglumic acid is differentiated from nitrogen-scavenging therapies by its mechanism and dosage form. It addresses urea-cycle activation rather than serving primarily as an alternative nitrogen-excretion substrate.

Product class	Representative products	Primary role	Excipient and formulation opportunity
Carglumic acid	Carbaglu and potential generics	Activates CPS I through N-acetylglutamate replacement	Dispersible tablets, granules, oral liquids
Sodium phenylbutyrate	Buphenyl, generic products	Nitrogen scavenging	Taste masking, sodium reduction, oral liquid or granules
Glycerol phenylbutyrate	Ravicti	Nitrogen scavenging	Liquid palatability, dosing-device optimization
Sodium benzoate combinations	Various hospital products	Nitrogen scavenging	Injectable or oral hospital formulations
Dialysis and intensive care	Non-drug intervention	Rapid ammonia removal	No direct excipient competition

Carglumic acid therefore has a distinct technical and clinical position. It is not readily replaced by a conventional generic of another ammonia-lowering drug.

What should a product-development team prioritize?

A development program should rank the following objectives:

1. Match the reference product's dispersion and dose-recovery performance.
2. Establish a moisture-controlled manufacturing and packaging system.
3. Build pediatric acceptability into the formulation from the first prototype.
4. Evaluate lower-strength and granule presentations only after the core 200 mg product is robust.
5. Map Orange Book patents and non-listed patent families before selecting the formulation.
6. Design a formulation that avoids unnecessary dependence on a narrow excipient combination.
7. Qualify multiple suppliers for the disintegrant, surfactant, and packaging components.
8. Generate comparative in-use stability data for the dispersed product.
9. Prepare indication-specific labeling and assess any method-of-use carve-out.
10. Use specialty distribution and regional licensing to control low-volume commercial risk.

Key Takeaways

• Carglumic acid is an orphan small-molecule metabolic drug, so biosimilar risk does not apply.
• The main reference product is Carbaglu 200 mg tablets for oral suspension.
• The key excipient functions are wetting, rapid disintegration, powder flow, compression, and tablet integrity.
• Croscarmellose sodium, sodium lauryl sulfate, microcrystalline cellulose, hypromellose, colloidal silicon dioxide, and talc are listed in the U.S. reference-product labeling.
• Generic value depends on equivalent dispersion, dose recovery, pediatric usability, and stable packaging.
• Lower-strength tablets, granules, and ready-to-use liquids are the clearest formulation opportunities.
• Historical orphan exclusivity periods have elapsed, but current patent and Orange Book analysis remains necessary for launch planning.
• Commercial opportunities are concentrated in generic supply, regional licensing, pediatric delivery, and manufacturing reliability.
• The most material formulation barriers are performance-based rather than ingredient-list based.

FAQs

Is carglumic acid a biologic requiring a biosimilar application?

No. Carglumic acid is a chemically synthesized small molecule. A competing product would generally follow a generic drug pathway rather than a biosimilar pathway.

Can carglumic acid be developed as an oral solution?

Yes, but an oral solution introduces preservative, microbial, packaging, in-use stability, taste, and shipping requirements that do not apply to a dry dispersible tablet to the same extent.

Which excipient is most important for a generic Carbaglu product?

The disintegrant and wetting system are central because the product must disperse uniformly in water. Croscarmellose sodium and sodium lauryl sulfate are listed in the reference-product labeling, but equivalence depends on finished-product performance rather than ingredient identity alone.

Are formulation patents more important than active-ingredient patents for carglumic acid?

Usually. For an established small molecule, the practical patent risk often shifts to dosage-form, method-of-use, manufacturing, stability, or packaging claims.

What is the strongest commercial differentiation for a carglumic acid generic?

Reliable pediatric administration. A product that disperses quickly, supports accurate dose measurement, has acceptable taste, and remains stable in moisture-protective packaging can compete on clinical usability and supply reliability.

References

1. U.S. Food and Drug Administration. (2024). Carbaglu (carglumic acid) tablets for oral suspension: Prescribing information.
2. U.S. Food and Drug Administration. (2016). E11(R1) addendum to ICH E11: Clinical investigation of medicinal products in the pediatric population.
3. U.S. Food and Drug Administration. (2023). Orphan drug designation and approval database.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. European Medicines Agency. (2024). Carbaglu: EPAR product information.